Gonzalo C. G. T.
- Country
- Spain
- Department
- Hematology Service
Research Overview
- Safety and Efficacy of Ponatinib Plus Asciminib Combination in Chronic Myeloid Leukemia Patients with Resistance to Ponatinib and/or Asciminib
- Evaluation of Bomedemstat Versus Best Available Therapy in Essential Thrombocythemia Patients with Hydroxyurea Intolerance or Inadequate Response
- Phase 3 Randomized Study of Bomedemstat vs. Hydroxycarbamide in Cytoreductive Therapy-Naïve Essential Thrombocythemia Patients
Data & Insights
Has run more than one trial at 52 of 133 partner sites.
Specializations
Hematologic Malignancies
The investigator specializes in treating chronic myeloid leukemia (CML) and its various manifestations, with particular attention to developing therapeutic solutions for different disease phases.
- Chronic Phase CML Management
- T315I Mutation Studies
- Novel Treatment Approaches
Their research extends to evaluating innovative therapeutic agents for patients with specific genetic mutations in CML.
Myeloproliferative Disorders
Focused expertise in treating essential thrombocythemia (ET), particularly in cases where conventional treatments have proven insufficient or intolerable.
- Therapy-Resistant ET
- Alternative Treatment Strategies
- Durable Response Assessment
The investigator explores advanced therapeutic options for patients who have experienced inadequate responses to standard treatments.
Therapeutic Innovation
Actively involved in evaluating novel therapeutic compounds for hematologic conditions, including targeted therapies and new treatment modalities.
- Safety and Tolerability Studies
- Pharmacokinetic Evaluation
- Treatment Efficacy Assessment
Their work encompasses the investigation of emerging treatments for various blood disorders, focusing on patient outcomes and therapeutic effectiveness.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.